||15 top-paid S&P 500 healthcare CEOs
||Becker's Hospital Review
||... CEO of Regeneron: $135.4 million2. Javier Rodriguez, CEO of Davita: $73.4 million 3. Samuel Hazen, CEO of Nashville, Tenn.-based HCA Healthcare: $30.4 million 4. Alex Gorsky, CEO of Johnson & Johnson: $29.6 million 5. Marc Casper , CEO of Thermo Fisher Scientific: $26.4 million 6. Ari Bousbib, CEO of Iqvia: $25.6 million 7. Michael Neidorff, CEO of Centene: $25 million 8. Richard Gonzalez, CEO of AbbVie: $24 million 9. David Ricks ...
||Waltham-based Thermo Fisher buying PPD in $17.4B deal
||... clinical research services and partner with them in new and exciting ways as they move a scientific idea to an approved medicine quickly, reliably and cost effectively,‚Äù said Thermo Fisher President and CEO Marc Casper .Shares of the Waltham-based company were up 3.5% in afternoon trading.PPD, based in Wilmington, N.C., is a contract-research company, which tests experimental drugs under development by pharmaceutical companies. The company provides ...
||5 ETFs to Make the Most of Thermo Fisher Deal to Buy PPD - April 16, 2021 - Zacks.com
||... create one of the biggest drug-testing companies in the United States. The acquisition of PPD expands Thermo Fishers‚Äô global reach in the attractive, high growth clinical research services industry. Thermo Fisher CEO Marc Casper stated that the deal is ‚Äúall about speed‚Äù in getting medicines to the market (read: JNJ Vaccine Pause Gives Stay-at-Home ETFs a Shot in the Arm ).The deal approved by the ...
||Thermo to Buy PPD for $17.4 Billion as Health Deals Soar
||... Inc., a provider of clinical and research services to the pharma and biotech industries, is ‚Äúall about speed‚Äù in getting medicines to market.That‚Äôs the message from Thermo Fisher Chief Executive Officer Marc Casper in outlining the company‚Äôs goals for the deal. Thermo Fisher will pay $47.50 a share for PPD, according to a statement Thursday, and will assume about $3.5 billion of net debt. The price ...
||Thermo Fisher to buy contract researcher PPD for $17.4 billion
||... 1.7 billion in 2019, and Patheon, a Dutch manufacturer of drugs for clinical trials, in 2017. ‚ÄúThe acquisition of PPD is a natural extension for Thermo Fisher,‚Äù said Thermo Fisher Chief Executive Officer Marc Casper . PPD, which went public last year, helps companies in the drug development process through preclinical consulting, designing and conducting clinical trials, and providing patient support. It was hired by Moderna Inc to oversee its ...
||Thermo Fisher Scientific Expands Pharma Presence with PPD
||... to provide these customers with important clinical research services and partner with them in new and exciting ways as they move a scientific idea to an approved medicine quickly, reliably and cost-effectively," said Marc Casper , chairman, president and CEO, Thermo Fisher Scientific. "Longer term, we plan to continue to invest in and connect the capabilities across the combined company to further help our customers accelerate innovation and drive productivity ...
||Thermo Fisher to buy contract research firm PPD for $17.4 billion
||... for $1.7 billion in 2019, and Patheon, a Dutch manufacturer of drugs for clinical trials, in 2017."The acquisition of PPD is a natural extension for Thermo Fisher," said Thermo Fisher Chief Executive Officer Marc Casper .PPD, which went public last year, helps companies in the drug development process through preclinical consulting, designing and conducting clinical trials, and providing patient support. It was hired by Moderna Inc to oversee its ...
||Thermo Fisher Jumps as Earnings and Revenue Beat Estimates
||... 6.83 billion.Analysts were expecting Thermo to report adjusted earnings of $6.56 a share on revenue of $9.58 billion.TMO "delivered the strongest year of performance in our company's history," Chief Executive Marc Casper said in a statement."From a financial perspective, we generated exceptional growth in revenue, earnings and free cash flow for the quarter and the year."Among the business segments, Thermo's life-sciences ...
||Thermo Fisher nets handheld COVID-19 test maker Mesa Biotech with $550M deal
||... The buyout follows the company‚Äôs recent $878 million pickup of Novasep‚Äôs Henogen division, which produces viral vectors used in certain COVID-19 vaccines and other treatments‚Äîand after Chairman, President and CEO Marc Casper said that 2021 would see Thermo Fisher quickly accelerate its long-term road map of M&A plans, as he outlined during last week‚Äôs annual J.P. Morgan healthcare conference.Casper also expects to ...
||JPM: Thermo Fisher picks up Novasep's viral vector business for $878M outright
||Earlier this week at the annual J.P. Morgan healthcare conference, Thermo Fisher Scientific CEO Marc Casper said 2021 is going to be a year that sees the company quickly accelerate its long-term plans, including a full pipeline of M&A deals. He wasn‚Äôt kidding.Buoyed by revenues from COVID-19 testing over the past year, Thermo Fisher announced that it has now acquired Henogen, Novasep's viral vector manufacturing ...
||Thermo Fisher reports $6bn+ COVID windfall in 2020
||... generating ‚Äúwell over $6 billion‚Äù in COVID-19 response revenue.Speaking at the JP Morgan Healthcare Conference, held virtually for the first time in its nearly 40 year history, Thermo Fisher Scientific CEO Marc Casper described 2020 as the ‚Äúbest year yet‚Äù for his firm, representing an ‚Äúextraordinary performance in the most challenging of times.‚ÄùThe multinational offers a broad spectrum of biopharma services, all of which ...
||JPM, Day 1: Sanofi grabs a British biotech, Regeneron hopes for FDA hold lift, Bluebird puts its eggs in 2 baskets, and more
||... Day 2 roundup covering the on-the-ground skinny from Tuesday's action.Monday 4:20 p.m. ETFollowing a year of unceasing demand for COVID-19 testing, Thermo Fisher Scientific‚Äôs chairman, president and CEO Marc Casper described 2020 as the strongest year in the company‚Äôs history‚Äîdriven not only by diagnostic sales, but also by its lab products for developers of coronavirus therapies and vaccines. Since last March, the ...
||Thermo Fisher, LabCorp, Quest see Q3 profits soar
||Becker's Hospital Review
||... have been nothing short of incredible for our company, and I‚Äôm truly humbled by our colleagues around the world who are making a meaningful and positive impact on society through their work," CEO Marc Casper said in the Securities and Exchange Commission filing.LabCorp reported that its third-quarter earnings more than tripled as COVID-19 testing demand surged and routine lab test volumes started to return to normal ...
||Mass General Brigham CFO: 5 insights on remote work & how to bring employees back onsite
||Becker's Hospital Review
||... working remotely, according to Boston-based Mass General Brigham CFO and treasurer Peter Markell. During a fireside chat at the World Medical Innovation Forum on May 11, Mr. Markell and Thermo Fisher Scientific CEO Marc Casper discussed how the COVID-19 pandemic has transformed the healthcare landscape, including the transition to working from home and the subsequent back-to-office transition. Five quotes from Mr. Markell: 1. On employee work ...
||The Top 50 Healthcare Technology CEOs of 2020
||... of leadership experience in the healthcare technology industry, level of expertise and domain knowledge in their particular field, depth of their executive team’s experience, and consistency of organizational performance. Topping this year’s list are Marc Casper , President and CEO of Thermo Fisher Scientific, Tom Polen, CEO of BD, and Brian Tyler, CEO of McKesson. Marc Casper ’s ascent to the top post of Thermo Fisher was rapid. After the company’s transformational ...
||Retailers, labs step up coronavirus testing as country preps to re-open
||... Walmart, Walgreens, CVS, Rite Aid and Kroger, LabCorp, Abbott Laboratories and more to discuss the states' capabilities in combating coronavirus. Afterward, Quest Diagnostics CEO Steve Rusckowski, LabCorp CEO Adam Schechter, Thermo Fisher Scientific CEO Marc Casper , U.S. Cotton CEO and president John Nims, CVS Health CEO and president Larry Merlo, Walgreens president Richard Ashworth, Kroger CEO Rodney McMullen, Walmart Inc. CEO and president Doug McMillon and Rite Aid CEO and ...
||POLITICO Playbook PM: Trump cancels his briefing, as Pelosi stays on air - Politico
||... and instead has opened up a 4 p.m. meeting with industry executives to the smaller White House press pool. THE PARTICIPANTS in the 4 p.m. event: Walgreens President Richard Ashworth; Thermo Fisher Scientific CEO Marc Casper ; Rite-Aid CEO Heyward Donigan; American Clinical Laboratory Association President Julie Khani; U.S. Cotton CEO and President John Nims; Walmart CEO Doug McMillon; CVS CEO Larry Merlo; CVS EVP Tom Moriarty; Quest Diagnostics Chairman ...
||More swabs, reagent available to ramp up testing in Ohio
||... working with the team this week had a major breakthrough working with Thermo Fisher that will substantially expand testing capacity in Ohio,” DeWine explained. “After their work, I talked directly with Thermo Fisher CEO Marc Casper , and we now have an agreement with them. This is an exciting, new partnership, and we look forward to working with the Thermo Fisher team and its 1,500 employees working in Ohio.” 2. Not ...
||Governor DeWine shares plan to increase coronavirus testing in Ohio
||... a) . (/a)DeWine says both Celeste and Taft had a major breakthrough working with Thermo Fisher, that will expand testing capacity in Ohio. (/p) "After their work, I talked directly with Thermo Fisher CEO Marc Casper , and we now have an agreement with them. This is an exciting, new partnership, and we look forward to working with the Thermo Fisher team and its 1,500 employees working in Ohio," said DeWine ...
||15,169 COVID-19 cases in Ohio; 1,817 in Cuyahoga County | Local News | clevelandjewishnews.com
||... coronavirus testing kits. The strike team led by former Ohio Govs. Dick Celeste and Bob Taft had a major breakthrough working with Thermo Fisher, DeWine said, and he talked directly with Thermo Fisher CEO Marc Casper . The state of Ohio now has a partnership with Thermo Fisher and its 1,500 employees working in Ohio to produce the reagent. An Ohio manufacturer of dental restorations will help address the shortage of ...